Science 2002;297:353-6
A meta-nalysis showed that, compared with placebo/no intervention, the treatment with acetyl-l-carnitine significantly decreased the symptoms of depression, with fewer adverse events than those seen with established antidepressants [94]
Shalender Bhasin, the TRAVERSE trial's principal investigator, stated: "Testosterone replacement therapy in middle-aged and older men with hypogonadism and cardiovascular risk did not increase the incidence of major cardiovascular events, but clinicians should still monitor for non-cardiac adverse effects" [7]
In just the first nine months of 2025, the pharmaceutical companies Novo Nordisk and Eli Lilly spent $700 million marketing their GLP-1 medications, Wegovy and Ozempic, and Zepbound and Mounjaro, respectively, according to Reuters
Honestly, the 50% off deal for the first month of Semaglutide was a big draw